Ashiq Mubarack's questions to Syndax Pharmaceuticals Inc (SNDX) leadership • Q3 2024
Question
Ashiq Mubarack from Citigroup Inc. asked about the differing maintenance therapy rates between the AUGMENT-101 and SAVE trials and questioned the rationale for focusing the frontline trial's primary endpoint solely on the NPM1 population.
Answer
CEO Michael Metzger and President Dr. Neil Gallagher explained that maintenance use is at physician discretion. Dr. Gallagher clarified the frontline trial is powered for NPM1 because that mutation is far more prevalent in the target older patient population, whereas KMT2A is more common in younger patients.